肯尼亚偏远地区儿童麻疹疫苗外展接种的经济价值模型研究
该研究利用免疫地理空间信息系统和麻疹 compartment 模型,量化肯尼亚24月龄以下地理偏远儿童(固定接种点服务半径外)两剂麻疹外展接种策略的健康与经济价值。外展策略在25%、50%、100% MCV1覆盖率下每避免1 DALY成本分别为76、122、274美元,具高度成本效果。
要点
- 偏远儿童不接种麻疹疫苗将导致1427例麻疹和7504 DALYs损失。
- 外展接种每避免1 DALY成本76-274美元,具高度成本效果。
- 支持投资有效的外展疫苗接种策略以覆盖地理偏远人群。
核心结论
- 在地理偏远人群中开展外展疫苗接种在多种场景下均具高度成本效果,支持投资有效的外展接种策略。
研究设计与样本
- 使用免疫地理空间信息系统平台和麻疹 compartment 模型,量化肯尼亚24月龄以下地理偏远儿童(固定接种点服务半径外)两剂麻疹外展接种策略的健康与经济价值。
主要发现
- 外展策略在25%偏远儿童接种MCV1时每避免1 DALY成本76(23-142)美元,50%时为122(40-226)美元,100%时为274(123-478)美元。
临床怎么用
- 决策者可参考外展接种的成本效果数据,支持对地理偏远人群的麻疹疫苗外展投资。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since special efforts are necessary to vaccinate people living far from fixed vaccination posts, decision makers are interested in knowing the economic value of such efforts. METHODS: Using our immunization geospatial information system platform and a measles compartment model, we quantified the health and economic value of a 2-dose measles immunization outreach strategy for children <24 months of age in Kenya who are geographically hard-to-reach (i.e., those living outside a specified catchment radius from fixed vaccination posts, which served as a proxy for access to services). FINDINGS: When geographically hard-to-reach children were not vaccinated, there were 1427 total measles cases from 2016 to 2020, resulting in $9.5 million ($3.1-$18.1 million) in direct medical costs and productivity losses and 7504 (3338-12,903) disability-adjusted life years (DALYs). The outreach strategy cost $76 ($23-$142)/DALY averted (compared to no outreach) when 25% of geographically hard-to-reach children received MCV1, $122 ($40-$226)/DALY averted when 50% received MCV1, and $274 ($123-$478)/DALY averted when 100% received MCV1. CONCLUSION: Outreach vaccination among geographically hard-to-reach populations was highly cost-effective in a wide variety of scenarios, offering support for investment in an effective outreach vaccination strategy.
引用
- Lee BY, Brown ST, Haidari LA, et al. Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya. Vaccine. 2019. PMID: 30922700. doi:10.1016/j.vaccine.2019.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。